1. Scrip

Theravance's Gut-Selective JAK Inhibitor Disappoints In Ulcerative Colitis Study

Crohn's Disease Data Awaited On Izencitinib

 
• By John Davis

Top-line results from a Phase IIb study of Theravance’s potential gut-selective JAK inhibitor izencitinib have not matched expectations, and results from a similar early-stage study in Crohn’s disease with the Janssen-partnered candidate are now awaited at the end of the year or in early 2022.

ulcerative colitis
• Source: Alamy

Theravance Biopharma Inc.’s gut selective JAK inhibitor izencitinib has missed primary and secondary efficacy endpoints in a Phase IIb ulcerative colitis study, dismaying the company which is now awaiting the results of a Crohn’s disease study with the compound, part of an ongoing collaboration with Janssen Biotech Inc..

There were high hopes that izencitinib would be a potent oral gut-selective pan JAK-inhibitor associated with few systemic side effects, but its lack of efficacy in the Phase IIb study also disappointed investors, with the company’s shares falling by 22%

More from Alimentary/Metabolic

More from Therapy Areas

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Merck’s Welireg Adrenal Tumor Rollout Targets Specialized Centers

 
• By Alaric DeArment

The drugmaker won US FDA approval for the HIF-2α inhibitor in pheochromocytoma and paraganglioma, a rare cancer of the adrenal glands, in adolescents and adults.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.